{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:44:14Z","timestamp":1787510654439,"version":"build-2736575974"},"reference-count":52,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer outcomes with chemotherapy are inferior in patients of minority racial\/ethnic groups and those with obesity. Chimeric antigen receptor (CAR) T-cell therapy has transformed outcomes for relapsed\/refractory hematologic malignancies, but whether its benefits extend commensurately to racial\/ethnic minorities and patients with obesity is poorly understood. With a primary focus on patients with B-cell acute lymphoblastic leukemia (B-ALL), we retrospectively evaluated the impact of demographics and obesity on CAR T-cell therapy outcomes in adult and pediatric patients with hematologic malignancies treated with CAR T-cell therapy across 5 phase 1 clinical trials at the National Cancer Institute from 2012 to 2021. Among 139 B-ALL CAR T-cell infusions, 28.8% of patients were Hispanic, 3.6% were Black, and 29.5% were overweight\/obese. No significant associations were found between race, ethnicity, or body mass index (BMI) and complete remission rates, neurotoxicity, or overall survival. Hispanic patients were more likely to experience severe cytokine release syndrome compared with White non-Hispanic patients even after adjusting for leukemia disease burden and age (odds ratio, 4.5; P\u00a0= .001). A descriptive analysis of patients with multiple myeloma (n\u00a0= 24) and non-Hodgkin lymphoma (n\u00a0= 23) displayed a similar pattern to the B-ALL cohort. Our findings suggest CAR T-cell therapy may provide substantial benefit across a range of demographics characteristics, including for those populations who are at higher risk for chemotherapy resistance and relapse. However, toxicity profiles may vary. Therefore, efforts to improve access to CAR therapy for underrepresented populations and elucidate mechanisms of differential toxicity among demographic groups should be prioritized.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007676","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T16:04:05Z","timestamp":1659974645000},"page":"6040-6050","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":49,"title":["The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4421-3767","authenticated-orcid":false,"given":"Aiman J.","family":"Faruqi","sequence":"first","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD"},{"name":"2Cleveland Clinic Lerner College of Medicine, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5513-1233","authenticated-orcid":false,"given":"John A.","family":"Ligon","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD"},{"name":"3Division of Hematology\/Oncology, Department of Pediatrics, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Borgman","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD"},{"name":"4Florida State University College of Medicine, Tallahassee, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"5Biostatistics and Data Management Section, National Cancer Institute, NIH, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Foley","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Little","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0359-9023","authenticated-orcid":false,"given":"Crystal L.","family":"Mackall","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD"},{"name":"6Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3249-9796","authenticated-orcid":false,"given":"Daniel W.","family":"Lee","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD"},{"name":"7Department of Pediatric Hematology\/Oncology, University of Virginia, Charlottesville, VA"},{"name":"8Department of Pediatrics, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8044-5226","authenticated-orcid":false,"given":"Terry J.","family":"Fry","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD"},{"name":"9University of Colorado Anschutz Medical Campus and Center for Cancer and Blood Disorders, Children\u2019s Hospital of Colorado, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haneen","family":"Shalabi","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Brudno","sequence":"additional","affiliation":[{"name":"10Surgical Oncology Branch, National Cancer Institute, NIH, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Yates","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lekha","family":"Mikkilineni","sequence":"additional","affiliation":[{"name":"10Surgical Oncology Branch, National Cancer Institute, NIH, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Kochenderfer","sequence":"additional","affiliation":[{"name":"10Surgical Oncology Branch, National Cancer Institute, NIH, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-9080","authenticated-orcid":false,"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"issue":"9","key":"2023053018335842000_bib1","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2023053018335842000_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2023053018335842000_bib3","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2023053018335842000_bib4","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"41","key":"2023053018335842000_bib5","first-page":"1","article-title":"CAR T-cell therapy in hematologic malignancies: clinical role, toxicity, and unanswered questions","volume":"41","author":"Gill","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10297","key":"2023053018335842000_bib6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"2023053018335842000_bib7","doi-asserted-by":"crossref","first-page":"e228161","DOI":"10.1001\/jamanetworkopen.2022.8161","article-title":"Enrollment of Black participants in pivotal clinical trials supporting US Food and Drug Administration approval of chimeric antigen receptor-T cell therapy for hematological malignant neoplasms","volume":"5","author":"Al Hadidi","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"7","key":"2023053018335842000_bib8","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"2023053018335842000_bib9","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1080\/10428194.2020.1779260","article-title":"Acute lymphoblastic leukemia mortality in Hispanic Americans","volume":"61","author":"Shoag","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2023053018335842000_bib10","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cncr.31989","article-title":"Neurotoxicity more likely in Hispanic children treated for acute lymphoblastic leukemia","volume":"125","author":"Printz","year":"2019","journal-title":"Cancer"},{"issue":"6","key":"2023053018335842000_bib11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/NCC.0000000000000872","article-title":"Hispanic children hospitalized with acute lymphoblastic leukemia are at increased risk of pancreatitis","volume":"44","author":"Savage","year":"2021","journal-title":"Cancer Nurs"},{"issue":"3","key":"2023053018335842000_bib12","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/1043454220907547","article-title":"A\u00a0literature review of racial disparities in overall survival of black children with acute lymphoblastic leukemia compared with white children with acute lymphoblastic leukemia","volume":"37","author":"Eche","year":"2020","journal-title":"J\u00a0Pediatr Oncol Nurs"},{"issue":"6","key":"2023053018335842000_bib13","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.26156","article-title":"Acute lymphoblastic leukemia: a population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017","volume":"96","author":"Sasaki","year":"2021","journal-title":"Am J Hematol"},{"issue":"8","key":"2023053018335842000_bib14","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1038\/s41375-021-01133-4","article-title":"Increased incidence of IKZF1 deletions and IGH-CRLF2 translocations in B-ALL of Hispanic\/Latino children\u2014a novel health disparity","volume":"35","author":"Raca","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"2023053018335842000_bib15","first-page":"5","article-title":"Lower 24-month relative survival among black patients with non-Hodgkin\u2019s lymphoma: an analysis of the SEER data 1997-2015","volume":"2","author":"Nieto","year":"2021","journal-title":"J\u00a0Clin Haematol"},{"issue":"8","key":"2023053018335842000_bib16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-020-00347-6","article-title":"Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis","volume":"10","author":"Derman","year":"2020","journal-title":"Blood Cancer J"},{"issue":"18","key":"2023053018335842000_bib17","doi-asserted-by":"crossref","first-page":"6825","DOI":"10.1002\/cam4.3334","article-title":"Body mass index associated with childhood and adolescent high-risk B-cell acute lymphoblastic leukemia risk: a Children\u2019s Oncology Group report","volume":"9","author":"Ghosh","year":"2020","journal-title":"Cancer Med"},{"issue":"7","key":"2023053018335842000_bib18","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1182\/bloodadvances.2020004018","article-title":"Caloric and nutrient restriction to augment chemotherapy efficacy for acute lymphoblastic leukemia: the IDEAL trial","volume":"5","author":"Orgel","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"2023053018335842000_bib19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.2021011106","article-title":"Increased prevalence of CRLF2 rearrangements in obesity-associated acute lymphoblastic leukemia","volume":"138","author":"Mittelman","year":"2021","journal-title":"Blood"},{"issue":"15","key":"2023053018335842000_bib20","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1200\/JCO.2006.07.7792","article-title":"Obesity and outcome in pediatric acute lymphoblastic leukemia","volume":"25","author":"Butturini","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023053018335842000_bib21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41375-021-01443-7","article-title":"A\u00a0comprehensive review of the impact of obesity on plasma cell disorders","volume":"36","author":"Parikh","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2023053018335842000_bib22","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s10552-014-0447-6","article-title":"Obesity and non-Hodgkin lymphoma survival in an ethnically diverse population: the Multiethnic Cohort study","volume":"25","author":"Leo","year":"2014","journal-title":"Cancer Causes Control"},{"issue":"12","key":"2023053018335842000_bib23","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1007\/s00262-020-02680-y","article-title":"Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"69","author":"Chen","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"2023053018335842000_bib24","doi-asserted-by":"crossref","first-page":"e001403","DOI":"10.1136\/jitc-2020-001403","article-title":"Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression \u2265\u00a050%: a multicenter study with external validation","volume":"8","author":"Cortellini","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"5","key":"2023053018335842000_bib25","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3390\/cancers12051230","article-title":"The effects of obesity on anti-cancer immunity and cancer immunotherapy","volume":"12","author":"Woodall","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2023053018335842000_bib26","author":"Christina Baggott","year":"2021"},{"issue":"9","key":"2023053018335842000_bib27","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.3324\/haematol.2021.280189","article-title":"Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 CAR-T in advanced B-cell malignancies","volume":"107","author":"Dos Santos","year":"2022","journal-title":"Haematologica"},{"issue":"4","key":"2023053018335842000_bib28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"27","key":"2023053018335842000_bib29","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2023053018335842000_bib30","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"3","key":"2023053018335842000_bib31","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2023053018335842000_bib32","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2023053018335842000_bib33","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.2022015795","article-title":"CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR","volume":"140","author":"Shalabi","year":"2022","journal-title":"Blood"},{"key":"2023053018335842000_bib34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fcell.2019.00074","article-title":"A\u00a0qualitative study exploring barriers and facilitators of enrolling underrepresented populations in clinical trials and biobanking","volume":"7","author":"Davis","year":"2019","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"2023053018335842000_bib35","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023053018335842000_bib36","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/OP.21.00001","article-title":"Participation of Black Americans in cancer clinical trials: current challenges and proposed solutions","volume":"17","author":"Awidi","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"24","key":"2023053018335842000_bib37","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.2217\/fon-2020-1262","article-title":"Race and ethnicity representation in clinical trials: findings from a literature review of phase I oncology trials","volume":"17","author":"Camidge","year":"2021","journal-title":"Future Oncol"},{"issue":"7","key":"2023053018335842000_bib38","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41408-021-00515-2","article-title":"The impact of obesity and body weight on the outcome of patients with relapsed\/refractory large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"11","author":"Wudhikarn","year":"2021","journal-title":"Blood Cancer J"},{"issue":"17","key":"2023053018335842000_bib39","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"2023053018335842000_bib40","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023053018335842000_bib41","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat Med"},{"issue":"22","key":"2023053018335842000_bib42","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T\u00a0cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"2023053018335842000_bib43","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T\u00a0cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2023053018335842000_bib44","doi-asserted-by":"crossref","first-page":"e26871","DOI":"10.1002\/pbc.26871","article-title":"An investigation of toxicities and survival in Hispanic children and adolescents with ALL: results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001","volume":"65","author":"Kahn","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"21","key":"2023053018335842000_bib45","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"13","key":"2023053018335842000_bib46","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2013.52.6962","article-title":"Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group","volume":"32","author":"Orgel","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"2023053018335842000_bib47","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2017-04-778225","article-title":"Racial and ethnic disparities in hematologic malignancies","volume":"130","author":"Kirtane","year":"2017","journal-title":"Blood"},{"key":"2023053018335842000_bib48","first-page":"noac034","article-title":"Neurotoxicity following CD19\/CD28\u03b6 CAR T-cells in children and young adults with B-cell malignancies","author":"Shalabi","year":"2022","journal-title":"Neuro-oncol"},{"issue":"7","key":"2023053018335842000_bib49","first-page":"350","article-title":"Systematic evaluation of neurotoxicity in children and young adults undergoing CD22 chimeric antigen receptor T-cell therapy","volume":"41","author":"Shalabi","year":"2018","journal-title":"J\u00a0Immunother"},{"key":"2023053018335842000_bib50","author":"Myers","year":"2021"},{"issue":"2","key":"2023053018335842000_bib51","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/bloodadvances.2020002439","article-title":"Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia","volume":"5","author":"Advani","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"2023053018335842000_bib52","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3322\/canjclin.54.2.78","article-title":"Cancer disparities by race\/ethnicity and socioeconomic status","volume":"54","author":"Ward","year":"2004","journal-title":"CA Cancer J Clin"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/23\/6040\/2054214\/blooda_adv-2022-007676-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/23\/6040\/2054214\/blooda_adv-2022-007676-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T14:35:06Z","timestamp":1685457306000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/23\/6040\/486137\/The-impact-of-race-ethnicity-and-obesity-on-CAR-T"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":52,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2022,12,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007676","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}